CLOs on the Move

OrbusNeich

www.orbusneich.com

 
OrbusNeich is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Sorenson Bioscience

Sorenson BioScience is a manufacturer of disposable plastic liquid handling products. Located in Salt Lake City, Utah, it was founded in 1981 as Mµlti Technology, Inc. The company rapidly became an innovator in the manufacture of liquid handling products

EIDAM DIAGNOSTICS CORPORATION

EIDAM DIAGNOSTICS CORPORATION is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

OrthoGrid Systems

OrthoGrid Systems is a rapidly expanding global leader in orthopedic imaging technology with specialized applications available or in development for hip arthroplasty, trauma, knee replacement, and other common procedures performed over 1 million times per year in aggregate in the USA and 3 million times globally. OrthoGrid helps to overcome the limitations of traditional low resolution, distorted imaging technology by providing computerized image correction and image guidance direction to physicians performing orthopedic procedures.

Panbio

Panbio is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.